TABLE 2.
Uni‐ and multivariate analyses of disease‐free survival (DFS) in each tumor location in DNA mismatch repair proficiency
| DFS | ||||
|---|---|---|---|---|
| Univariate | Multivariate | |||
| HR(95% CI) | P‐value | HR (95% CI) | P‐value | |
| Right‐sided | ||||
| Sex (M vs F) | 0.6220 (0.1462‐2.6455) | .5058 | — | — |
| Age (≤70 vs 70<) | 2.5263 (0.5955‐10.718) | .1987 | — | — |
| Tumor depth (T1‐2 vs T3‐4) | 1.4230 (0.0760‐8.0387) | .7525 | — | — |
| Lymph node metastasis (− vs +) | 0.5232 (0.1279‐2.5580) | .3924 | — | — |
| Tumor differentiation (well/mod vs others) | 0.3386 (0.0772‐2.3240) | .2318 | — | — |
| Lymphatic invasion (− vs +) | 0.5531 (0.1132‐2.2516) | .4080 | — | — |
| Venous invasion (− vs +) | 1.9345 (0.3957‐7.9113) | .3839 | — | — |
| Perineural invasion (− vs +) | not estimated | .1240 | — | — |
| HLA classI (low vs high) | 0.4950 (0.1012‐2.0265) | .3279 | — | — |
| HLA classII (low vs high) | 0.5922 (0.1214‐2.4163) | .4663 | — | — |
| tPD‐L1 (low vs high) | 1.0683 (0.2509‐4.5490) | .9260 | — | — |
| sPD‐L1 (low vs high) | 2.1146 (0.5135‐10.407) | .2993 | — | — |
| PD‐1 (low vs high) | 2.9767 (0.6845‐20.334) | .1516 | — | — |
| CTLA‐4 (low vs high) | 0.9789 (0.2312‐4.1445) | .9760 | — | — |
| CD3 (low vs high) | 3.6488 (0.8367‐24.968) | .0868 | — | — |
| CD4 (low vs high) | 2.1619 (0.5256‐10.629) | .2848 | — | — |
| CD8 (low vs high) | 3.7213 (0.8541‐25.451) | .0817 | — | — |
| TIA‐1 (low vs high) | 4.5348 (1.0431‐30.969) | .0435* | 2.3141 (0.4948‐16.784) | 0.3010 |
| T‐bet (low vs high) | 0.6873 (0.1409‐2.8030) | .6032 | — | — |
| GATA3 (low vs high) | 3.4926 (0.7988‐23.938) | .0992 | — | — |
| Foxp3 (low vs high) | 10.642 (1.8744‐199.65) | .0052* | 7.6445 (1.2091‐150.35) | 0.0284* |
| RorγT (low vs high) | 1.1726 (0.2772‐4.9607) | .8220 | — | — |
| CD163 (low vs high) | 1.7702 (0.4341‐8.6335) | .4264 | — | — |
| Left‐sided | ||||
| Sex (M vs F) | 1.3592 (0.5645‐3.7677) | .5085 | — | — |
| Age (≤70 vs 70<) | 1.3729 (0.5858‐3.5732) | .4763 | — | — |
| Tumor depth (T1‐2 vs T3‐4) | 0.3869 (0.0216‐1.8445) | .2809 | — | — |
| Lymph node metastasis (N− vs N+) | 0.4422 (0.1778‐1.0194) | .0556 | — | — |
| Tumor differentiation (well/mod vs others) | 0.1198 (0.0498‐0.3190) | .0001* | 0.0975 (0.0289‐0.3185) | 0.0002* |
| Lymphatic invasion (− vs +) | 0.3804 (0.1370‐0.9178) | .0308* | 0.5718 (0.1832‐1.5692) | 0.2860 |
| Venous invasion (− vs +) | 0.2495 (0.0399‐0.851) | .0237* | 0.1751 (0.0234‐0.7904) | 0.0213* |
| Perineural invasion (− vs +) | 0.3462 (0.1510‐0.8357) | .0197* | 0.6546 (0.2561‐1.7916) | 0.3959 |
| HLA classI (low vs high) | 1.5318 (0.6718‐3.6781) | .3127 | — | — |
| HLA classII (low vs high) | 1.6024 (0.7023‐3.8497) | .2642 | — | — |
| tPD‐L1 (low vs high) | 1.2984 (0.5694‐3.1178) | .5379 | — | — |
| sPD‐L1 (low vs high) | 2.3519 (1.0210‐5.8450) | .0445* | 1.9256 (0.7099‐5.2939) | 0.1952 |
| PD‐1 (low vs high) | 1.1986 (0.5253‐2.7622) | .6642 | — | — |
| CTLA‐4 (low vs high) | 1.6485 (0.7246‐3.8642) | .2325 | — | — |
| CD3 (low vs high) | 0.9694 (0.4205‐2.2126) | .9406 | — | — |
| CD4 (low vs high) | 1.3970 (0.6141‐3.2749) | .4248 | — | — |
| CD8 (low vs high) | 1.6932 (0.7425‐4.0657) | .2117 | — | — |
| TIA‐1 (low vs high) | 1.5849 (0.6950‐3.8055) | .2753 | — | — |
| T‐bet (low vs high) | 0.7746 (0.3306‐1.7611) | .5421 | — | — |
| GATA3 (low vs high) | 1.9569 (0.8498‐4.8618) | .1159 | — | — |
| Foxp3 (low vs high) | 1.0084 (0.4373‐2.3027) | .9841 | — | — |
| RorγT (low vs high) | 1.6612 (0.7281‐3.9908) | .2292 | — | — |
| CD163 (low vs high) | 1.3319 (0.5856‐3.1216) | .4940 | — | — |
Abbreviations: CI, confidence interval; DFS, disease ‐ free survival; F, female; HR, hazard ratio; M, male; mod, moderate; PD‐1, programmed cell death‐1; sPD‐L1, programmed cell death‐ligand 1 in stromal cells; tPD‐L1, programmed cell death‐ligand 1 in tumor cells.
*
P < .05.